NEO Short Interest Climbs as Bears and Bulls Dig In Before the Print

NeoGenomics arrives at tonight's earnings release with short sellers meaningfully more active than they were just weeks ago — and options hedging still running well above its recent baseline.

Short interest has accelerated sharply since the prior earnings preview. At 10.3% of the free float, the short position has grown 16% over the past week and 47% over the past month — a notable step-up from the 8.9% level flagged in the July 25 article. That build is worth watching, but the lending market is not yet signalling distress. Borrow availability is loose at 343% of outstanding short interest, comfortably within normal territory, and the cost to borrow sits at a benign 0.52%. Bears have added to their positions, but they are doing so with room to spare and at minimal carrying cost.

Options positioning has remained elevated through the run-up to the print. The put/call ratio hit 0.052 on Tuesday, more than two standard deviations above its 20-day average of 0.017 — consistent with the defensive tilt identified ahead of the July 28 date. The stock gave back another 7% on the week to close at $13.40, paring the month's losses to roughly 5%. Correlated peers have also weakened: PRVA dropped 6% on the week, and NUTX fell nearly 8%, suggesting broader sector pressure rather than NEO-specific selling.

The bull and bear divide is clearest on the revenue mix. Bulls point to gross margin expansion — 150 basis points to 46.8% — and NGS testing revenue growth of 18% in Q1, alongside an EPS momentum score ranking in the 94th percentile on a 90-day basis. Benchmark raised its price target to $16 just last week, maintaining its Buy rating, and the consensus mean target implies roughly 25% upside from current levels. Bears counter with non-clinical sales that missed consensus by nearly 15%, ongoing reimbursement risk, and a PE multiple near 45x on a stock that remains loss-making on reported figures. The ORTEX short score of 60.2 is elevated but stable, suggesting the market is pricing in genuine uncertainty rather than one-directional conviction.

The print tonight tests whether the margin story has legs — specifically whether the operating improvements that drove analyst upgrades earlier this year are durable enough to absorb the revenue-mix headwinds that have kept short sellers engaged.